Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. George Dover

George J Dover, M.D.

Director Johns Hopkins Children's Center
Professor of Pediatrics

Male

Appointment Phone

410-955-6132

Main Location

The Johns Hopkins Hospital

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Director Johns Hopkins Children's Center
  • Given Professor and Director Department of Pediatrics
  • Pediatrician-in-Chief, Johns Hopkins Children’s Center
  • Professor of Pediatrics
  • Joint Appointment in Medicine
  • Professor of Oncology

Centers & Institutes

Departments

Locations

The Johns Hopkins Hospital

Appointment Phone: 410-955-6132

600 N. Wolfe Street
Sheikh Zayed Tower
Baltimore, MD 21287 map
Phone: 410-955-5976
Fax: 410-955-9850

Expertise

Pediatric Hematology Oncology

Biography

Given Professor of Pediatrics George J. Dover, M.D., is the director of the Department of Pediatrics at the Johns Hopkins University School of Medicine and pediatrician-in-chief of the Johns Hopkins Children’s Center.

Former director of the division of pediatric hematology at Johns Hopkins, Dr. Dover has a long history in the study and treatment of sickle cell disease (SCD), a genetic condition that affects nearly 100,000 Americans, most of them African American, as well as people of Middle Eastern and Mediterranean descent. This disease is named for the unusually sickle-shaped red blood cells that the condition causes. Sickle cell disease causes red blood cells, the body’s transporters of oxygen, to become rigid, which in turn reduces their oxygen delivery to vital organs and causes cells to get stuck in the blood vessels, leading to severe pain and so-called “sickling crises,” which require transfusion and hospitalization.

Dr. Dover was responsible for many of the initial observations of the biology and genetic control of fetal hemoglobin, a type of hemoglobin that makes red blood cells less likely to bend and clump. He became one of the pioneers in the area of pharmacologic manipulation of fetal hemoglobin, and has made many substantial contributions to the field. Along with Johns Hopkins’ Samuel Charache, M.D., Dr. Dover discovered that the cancer drug hydroxyurea can boost fetal hemoglobin and decrease the excruciating pain of sickling crises, as well as respiratory complications known as acute chest syndrome. The discovery catalyzed the drug’s FDA approval for treatment of sickle cell disease pain crises. To date, hydroxyurea remains the only FDA-approved drug for treatment of such episodes.

A 1968 graduate of Washington and Lee University, Dr. Dover received his medical degree from 1972 from Louisiana State University Medical School in New Orleans. He trained in pediatrics at Johns Hopkins Hospital, where he also completed a fellowship in pediatric hematology/oncology before joining the Hopkins faculty in 1977 as an instructor and a research associate in the Howard Hughes Medical Institute for Human Biochemical Genetics.

Moving up the ranks at Johns Hopkins, Dr. Dover directed the division of pediatric hematology from 1990 to 1996 until his appointment in 1995 as director of both the department of pediatrics and the Johns Hopkins Children’s Center. In recent years, he led faculty and staff in the development and design of the Charlotte R. Bloomberg Children’s Center, a state-of-the-art pediatric building on Johns Hopkins’ East Baltimore campus, which opened in May of 2012.

The author of over 100 peer-reviewed publications as well as author or co-author of more than 26 book chapters in the fields of pediatric hematology and genetics, Dr. Dover has been a consultant on numerous NIH grants and is active in federal government advisory committees. He was the chairman of both the NHLBI hematology study section and the DSMB for the NIH Comprehensive Sickle Cell Centers and also a board member of the Cooley’s Anemia Foundation.

His research in molecular biology and genetics, thalassemia and sickle cell disease was continuously funded by the NIH at the R01 level for over 20 years. In addition, he has been the principal investigator on two NIH-funded training grants: the “Child Health Research Career Development Award” and the National Institute of Child Health and Human Development’s “Institutional Training for Pediatricians.”

Dr. Dover is a recipient of the George J. Stuart Award for Outstanding Clinical Teaching, given by the senior medical students at Johns Hopkins; the Alexander Schaffer Award for Outstanding Teaching of the Harriet Lane Pediatric Residents; and the MERIT Research Award from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH).

In 2016 Dr. Dover will have led the JHCC and the Department of Pediatrics for 20 years. During that time the faculty have increased by 30%, 13 new endowed professorships have been obtained, The David Rubenstein Outpatient Building for the Harriet Lane Clinic and the pediatric specialty clinics was opened, the new Charlotte R. Bloomberg Children's Center at Johns Hopkins has opened and the All Children's Hospital in St. Petersburg, Florida has been incorporated into the Johns Hopkins Health System. 

...read more

Featured Video

George Dover on ‘Beyond Bricks and Mortar

More Videos

    Additional Information

  • Education +

    Degrees

    • Louisiana State University School of Medicine / M.D. (1972)

    Residencies

    • Johns Hopkins University School of Medicine / Pediatrics (1975)

    Certifications

    • American Board of Pediatrics / Pediatric Hematology-Oncology (1978)
    • American Board of Pediatrics / Pediatrics (1976)
  • Research & Publications +

    Research Summary

    Dr. Dover’s research in molecular biology and genetics, thalassemia and sickle cell disease was continuously funded by the NIH at the R01 level for over 20 years.

    He, along with colleague Samuel Charache, M.D., discovered that the cancer drug hydroxyurea can boost fetal hemoglobin and decrease the excruciating pain of sickling crises, as well as respiratory complications known as acute chest syndrome. As a result, the FDA approved hydroxyurea for the treatment of sickle cell disease pain crises. Hydroxyurea remains the only FDA-approved drug for treatment of such episodes.

  • Academic Affiliations & Courses +
  • Activities & Honors +

    Honors

    • Alexander Schaffer Award for Outstanding Teaching of the Harriet Lane Pediatric Residents, Johns Hopkins
    • George J. Stuart Award for Outstanding Clinical Teaching
    • MERIT Research Award, National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH)

    Memberships

    • Chair, NHLBI Hematology Study Section
    • Chair, Data and Safety Monitoring Board, NIH Comprehensive Sickle Cell Centers
    • Board member, Cooley’s Anemia Foundation
    • The Johns Hopkins Home Care Group Board of Trustees Advisory Council, Institute for Basic Biomedical Sciences, Johns Hopkins
    • Chairman, Clinical Scientists Award Selection Committee, Office of Research Administration, Johns Hopkins
    • The Johns Hopkins Urban Medicine and Pediatrics Primary Care Leadership Training Program, Johns Hopkins Bayview Medical Center, 2009 - 2009
    • Chair, Committee on Faculty Recruitment and Diversity, 2003
  • Videos & Media +

    Videos

    Part 1, Genetics and Pediatrics: Beyond Genomics

    Part II, Genetics and Pediatrics: Beyond Genomics

    Part III, Genetics and Pediatrics: Beyond Genomics

    Building a Dialogue: Webisode 10

    Building a Dialogue: Webisode 15

    Recent News Articles & Media Coverage

Is This You? Edit Profile
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.